Prescient Therapeutics Limited (PSTTF) Comparison with companies in other sectors?

Prescient Therapeutics Limited has a share price of 810.53M. You can analyze Prescient Therapeutics Limited (PSTTF) competitors across different market sectors through stock heatmaps.

What are PSTTF's NET and operating margins?

Prescient Therapeutics Limited (PSTTF) operating margin is around N/A, and net profit margin is approximately N/A as of the latest reports.

In what way does PSTTF's earnings per share (EPS) trend reflect its financial momentum?

Prescient Therapeutics Limited (PSTTF) EPS is -0.01 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Prescient Therapeutics Limited is -29.00, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Prescient Therapeutics Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Prescient Therapeutics Limited like P/E which is N/A, P/B which is N/A, and PEG which is N/A. Compare them with sector averages to evaluate if the stock is priced fairly.

Prescient Therapeutics Limited

PSTTF•PNK

Healthcare

Biotechnology

$0.14

$0.00(0.00%)

Prescient Therapeutics Limited (PSTTF) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.01

P/E Ratio

-29.00

ROE

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$117.53M

Shares OutstandingTotal number of shares issued

$810.53M

Book Value/ShareNet worth per share

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.005

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

ROAReturn on total assets

ROCEReturn on capital employed

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for PSTTFFinancial Ratios Analysis details for PSTTF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for PSTTFSector Benchmarking details for PSTTF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Prescient Therapeutics Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Prescient Therapeutics Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Prescient Therapeutics Limited's unique business strengths and challenges.

Key Financial Metrics for Prescient Therapeutics Limited

For Prescient Therapeutics Limited, essential financial indicators include EPS -0.01, PE -29.00, and ROE -. These key ratios reveal insights into Prescient Therapeutics Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Prescient Therapeutics Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Prescient Therapeutics Limited

Metrics like Net Margin - and ROA - shed light on how well Prescient Therapeutics Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Prescient Therapeutics Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Prescient Therapeutics Limited

Using ratios such as P/B Ratio - and PEG Ratio -, investors can assess whether Prescient Therapeutics Limited is appropriately valued based on its financials and growth potential. These figures, combined with Prescient Therapeutics Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Prescient Therapeutics Limited

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow -, provide a snapshot of Prescient Therapeutics Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Prescient Therapeutics Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Prescient Therapeutics Limited

Investing in Prescient Therapeutics Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Prescient Therapeutics Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;